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TUMOUR HYPOXIA AND BIOREDUCTIVE DRUGS
The development of a blood supply to provide oxygen and nutri-
ents is essential for growth in a solid tumour. The chaotic and/or
incomplete nature of the developing tumour vasculature results in
disrupted delivery of oxygen creating subpopulations of cells
which are either acutely or chronically hypoxic. Cycles of acute
hypoxia/normoxia occur close to blood vessels due to intermittent
vascular collapse. Cells distant (~70–150 microns) from a feeder
vessel will become chronically hypoxic. These hypoxic cells are a
significant problem in the control of solid tumours since they are
2–3 times more resistant to radiotherapy and are less sensitive to
most chemotherapeutic agents (Brown, 2000). In addition,
absence of oxygen promotes a stress response which may favour
development of a more malignant phenotype (Graeber et al, 1996).
Efforts to eradicate hypoxic cells have led to the preclinical
development of a number of bioreductive drugs. These are
predominantly based on nitro or quinone functionality that can be
reduced to covalent modifiers of DNA in hypoxic cells (reviewed
in Patterson and Raleigh, 1998). Since hypoxia is found in
tumours this provides for targeting of chemotherapy.
Tirapazamine, a benzotriazene-di-N-oxide, was the first agent, not
based on a nitro or quinone functionality, to exhibit a significant
increase in cytotoxicity under hypoxic conditions. However
Tirapazamine does exhibit some toxicity to oxic cells probably via
a reactive oxygen species generated from reductase mediated
redox cycling (Saunders et al, 2000). The recent success of
Tirapazamine in clinical trials has championed the development of
bioreductive drugs beyond preclinical rationalization (Brown,
1999).
Ideally a bioreductive prodrug should show minimal toxicity in
oxic cells. In hypoxic cells it should be converted by an enzymic
process, inhibited by oxygen, to a stable persistent cytotoxin. This
would ensure that the prodrug, once reduced, will maintain
activity should oxygen reperfusion occur. The product should bind
non-covalently to DNA with an affinity high enough to produce
cytotoxicity and low enough to allow slow diffusion and subse-
quent cytotoxicity in proximate tumour cells irrespective of their
oxygen levels. AQ4N is an N-oxide of a DNA affinic agent that
was rationalized to fulfil such requirements (Patterson, 1993).
PHYSICAL PROPERTIES AND ASSAY OF AQ4N
AQ4N is the di-N-oxide of 1,4-bis[{2-(dimethylaminoethyl}-
amino]5,8-dihydroxyanthracene-9,10-dione (AQ4), analkylamino-
anthraquinone (see Figure 1). No detectable DNA binding could
be shown in studies to determine the potential of AQ4N as a
prodrug of a DNA-directed cytotoxic. In contrast its reduction
product, AQ4, has a high DNA affinity constant which stabilizes
the DNA double helix as measured by a large increase in DNA
melting temperature. DNA binding of the AQ4 chromophore is
greatly facilitated by the δ + nature of the alkylamino side chains
in the protonated form that allows for a critical electrostatic inter-
action with phosphates of the DNA backbone. In contrast, the
δ – partial charge on the N-oxide functionality of AQ4N makes
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Figure 1 AQ4N and its reduction metabolites
http://www.bjcancer.comsuch an interaction impossible; indeed, the electrostatic interaction
with the DNA phosphates is repulsive. Hence AQ4N does not
undergo a stable interaction with DNA.
The physical properties of AQ4N are considerably different to
the active metabolite, AQ4. As an N-oxide of an aliphatic amine,
AQ4N has salt-like properties which confer high aqueous solu-
bility (260 mg ml–1). This facilitates greatly the handling and
formulation of AQ4N which has been routinely administered in
water in all preclinical studies in vitro and in vivo. To assist in
the large scale preparation for preclinical toxicology and clinical
evaluation, AQ4N has been prepared as the dihydrochloride (Lee
and Denny, 1999). The AQ4N.2HCl addition salt is possible
because the N-oxide functionality retains basicity although consid-
erably less so than AQ4. AQ4N.2HCl dissociates in aqueous
solution and is indistinguishable from AQ4N. Since AQ4N is ther-
molabile at autoclave temperature (120° C) it cannot be heat steril-
ized. Instead it is formulated with phosphate salts as a filter
sterilized, lyophilized powder which upon reconstitution with
water provides a 40 mg ml–1, pH 7.0 injection buffered solution.
Studies have shown that aqueous solutions of AQ4N are stable at
4° C (for 28 days). Hence refrigeration is the preferred method of
storage following reconstitution.
AQ4N is reduced to AQ4 through an obligate mono-N-oxide
intermediate (AQM) and the final reduction product AQ4 (see
Figure 1). To facilitate metabolism and pharmacokinetic studies a
reverse phase HPLC method of analysis has been developed
(Swaine et al, 2000). AQ4N is both hydrophilic and electrically
neutral whilst AQ4 is extremely hydrophobic but cationic at acid
pH. AQM retains cationic charge but is less hydrophobic.
Detection is maximal at 242 nm although 267 nm, 612 nm and
662 nm can also be used consistent with the intense blue colour of
AQ4N. AQ4N and AQ4 can also be visualized using flow cytom-
etry and laser-scanning confocal fluorescence microscopy (Smith
et al, 1997a). This is possible because both agents have intrinsic
fluorescence in the far-red (650–800 nm) when illuminated with a
Krypton laser (excitation at 647 nm or 514 nm).
TUMOUR CELL AND TOPOISOMERASE II
TARGETING BY AQ4N
When AQ4N (NSC 673504) was tested, in oxic conditions, against
the National Cancer Institute (USA) panel of 60 tumour cell lines
little or no cytotoxicity was observed (IC50 >100 µ M). In other
studies, where reduction was facilitated, potent cytotoxicity was
observed in the nM range (Patterson, 1993; Wilson et al, 1996;
Smith et al, 1997b). In vitro the differential activity of AQ4N, to
its active metabolite AQ4, is considerably greater than any
other N-oxide described including DACA-N-oxide and nitracrine
N-oxide (Wilson et al, 1996). Decreasing the cell culture medium
to pH 6.5 had little effect on the cytotoxicity of AQ4 suggesting
that its activity will be retained even if the hypoxic target cells are
in regions of low extracellular pH.
Cellular uptake and subcellular distribution of AQ4N and AQ4
in single cells has been studied using flow cytometry and laser-
scanning confocal fluorescence microscopy. These studies show
cytoplasmic sequestration but not nuclear fluorescence of AQ4N.
In contrast AQ4 is shown to be sequestered in the cytoplasm,
nuclear membrane and intranuclear compartment. Following a 2 h
incubation in drug-free medium as little as 1% of AQ4N was
retained in the cells. In contrast up to 26% of AQ4 was retained in
cells demonstrating the persistence of the cytotoxic metabolite
(Smith, 1997a). This also demonstrates that the majority of AQ4,
once formed is available to permeate into proximate tumour cells
possibly affording a ‘bystander’ effect.
Topoisomerase II targeting by the DNA affinic AQ4 has been
well documented (Patterson, 1993; Smith et al, 1997b). In contrast
studies have shown that AQ4N was not able to inhibit decatena-
tion of (kinetoplast) DNA by nuclear extract containing topoiso-
merase II (Patterson, 1993; Smith et al, 1997b). AQ4N showed no
topoisomerase II trapping in cells with low (MRC5-V1) or
elevated (AT5BIVA) topoisomerase II alpha expression as
measured using K+ SDS revealed DNA-protein cross-linking.
Importantly, the cytotoxic reduction product, AQ4, showed higher
total DNA crosslinking and more persistent enzyme trapping in
the topoisomerase II overexpressing cell line. Consistent with this,
the cytotoxicity of AQ4 was enhanced 21-fold in the topoiso-
merase II overexpressing cell line. The resistance of non-cycling
cells to AQ4N and AQ4, as shown by a decreased cytotoxicity to
plateau phase cells, is consistent with topoisomerase II poisoning
as the major mechanism of action (Wilson et al, 1996). This may
offer AQ4N a therapeutic advantage since it will limit the toxicity
experienced by normal tissue which is predominantly composed of
non-dividing cells. This is in addition to the fact that very limited
metabolism of AQ4N should occur in normal tissues since they are
normally adequately oxygenated.
METABOLIC ACTIVATION OF AQ4N
Although it was rationalized that AQ4N would undergo bioreduc-
tion in hypoxic cells, early preclinical development of AQ4N was
confounded by the lack of activity of AQ4N in several cell lines
incubated under hypoxic conditions. Reduction of AQ4N to an in
vitro cytotoxic product was only shown when liver microsomal
fractions, known to be rich in cytochrome P450, were added to
cultured cells. An over 100-fold increase in cytotoxicity was
obtained when cells were incubated under hypoxic conditions with
NADPH supplemented microsomes (Patterson, 1993). However,
AQ4N is not activated by NAD(P)H-dependent cytochrome P450
reductase per se (Patterson et al, 1999), although this enzyme is
well characterized as the reductase involved in nitro and quinone
bioreductive drug activation and as a contributor to Tirapazamine
activation (Patterson et al, 1998; Saunders et al, 2000). In the
development of bioreductive drugs, the lack of activation of
AQ4N by CPR is unique and is an advance on conventional bio-
reductives. This is because AQ4N, by comparison with other 1,4-
disubstituted alkylaminoanthraquinones does not undergo
cytochrome P450 reductase driven redox cycling and reactive
oxygen formation (Fisher and Patterson, 1992). In contrast nitro
and quinone based bioreductives as well as Tirapazamine all
generate reactive oxygen under oxic conditions. Subsequently the
lack of AQ4N metabolism in vitro was explained by the well
recognized down-regulation of cytochrome P450 (CYP) expres-
sion in cell culture conditions. Indeed it was shown that excised
tumour cells had the ability to metabolize AQ4N if exposed to
hypoxic conditions and drug immediately on removal from a
mouse; this activity was lost within 24 hours (Hejmadi et al,
1996).
Several studies have now addressed the nature of the CYP
isoforms involved in AQ4N reduction. In humans the metabolism
of AQ4N correlates significantly with the CYP3A subfamily of
enzymes as measured using phenotyped liver microsomes as a
mixed source of CYP (Raleigh et al, 1998). Using commercially
1590 LH Patterson and SR McKeown
British Journal of Cancer (2000) 83(12), 1589–1593 © 2000 Cancer Research Campaignavailable recombinant CYPs (so-called supersomes), CYP1A1 and
2B6 are amongst the most efficient isoforms responsible for
AQ4N reduction (unpublished data). In any given human tumour
the full complement of CYPs expressed is not known. AQ4N
reduction in a particular tumour is likely to be dependent on the
presence of CYP1A, 2B6 and 3A and/or other as yet unidentified
CYP isoforms. In the mouse CYP3A appears to play a role in
AQ4N reduction consistent with some human studies (Patterson et
al, 2000). However in the rat, inhibitor and induction studies show
that CYP2B and 2E but not 3A are involved in AQ4N reduction
(Raleigh et al, 1999) suggesting caution when interpreting CYP
profiles is warranted. The specific mechanism of AQ4N reduction
by CYPs is not known but given the requirement for NAD(P)H,
native enzyme preparations and its inhibition by oxygen and
carbon monoxide, it is likely that N-oxide interaction with the
CYP haem-centred active site is required to facilitate
nitrogen–oxygen bond cleavage. Essentially, reduction of the two
N-oxide functionalities of AQ4N is likely to involve an oxygen
atom transfer from the N-oxide side chains. This process is air
sensitive, presumably because oxygen can out-compete AQ4N for
haem binding.
There is some evidence that haem containing systems other than
CYPs can mediate AQ4N reduction. A preliminary study has
shown that recombinant nitric oxide synthase (NOS) reduces
AQ4N (Raleigh, 1998). NOS is a homodimeric protein comprising
a carboxy-terminal reductase domain resembling cytochrome
P450 reductase and a P450-like N-terminal domain. Other
chemotherapeutic agents including tirapazamine are substrates for
several isoforms of NOS (Garner et al, 1999) and NOS is shown to
be highly expressed in tumours (Thomsen et al, 1994, 1995).
AQ4N REDUCTION IN TUMOURS
AQ4N is reduced to AQ4 in renal cell carcinoma microsomes
(Patterson et al, 1999) which were also shown histochemically to
express CYP (Murray et al, 1999). The carcinomas did not contain
normal renal cells as monitored by histological examination.
Colon adenocarcinoma microsomes also reduced AQ4N to its
active metabolite (Patterson and Raleigh, unpublished results).
The tumour expression of appropriate reductases is an important
determinant in the potential of AQ4N activation to a cytotoxic
metabolite. With this in mind, AQ4N-based prodrug therapy is
likely to be an effective treatment regimen for a large number of
patients with solid tumours since several drug metabolizing CYP
isoforms have been detected in a broad spectrum of human cancers
(reviewed in Patterson et al, 1999).
AQ4N: DEFINING A MAXIMUM TOLERATED
DOSE IN VIVO
It was observed that normoxic mice tolerated single doses up to
320 mg kg–1 in the hypobaric chamber experiments (McKeown et
al, 1995). In two studies over 400 mg kg–1 was tolerated (Wilson et
al, 1996, Bibby, personal communication); this has since been
confirmed by preclinical toxicity trials carried out by BIBRA
(personal communication). However the drug activity shows only
a weak dependence on dose and between 100–200 mg kg–1 an
almost maximal anti-tumour effect is observed in growth delay of
T50/80 tumour (McKeown et al, 1996). A similar maximal
measurable effective limit is found at 200 mg kg–1 in the SCCVII
tumour using a clonogenic assay (Patterson et al, 2000).
AQ4N AND HYPOXIA IN VIVO
The first demonstration that AQ4N had potential in vivo as a
hypoxic cell cytotoxin was shown using a hypobaric chamber
(McKeown et al, 1995). Previously this model system was used to
show that the anti-tumour efficacy of Tirapazamine was signifi-
cantly enhanced when mice were placed in a chamber at 0.5 atm
(i.e. 10% oxygen) for 24 h following a single dose of a drug
(McAleer et al, 1992). In the hypoxic chamber systemic toxicity
was only minimally enhanced for AQ4N, whereas it was appre-
ciable for Tirapazamine. This suggested that AQ4N had a minimal
increase in metabolism in systemic tissues when the oxygen
tension was lowered. In contrast, Tirapazamine is metabolized at
all oxygen tensions and its bioreductive potential relates to the
increased metabolism with low oxygen levels (Koch, 1993).
Further support of the critical role of hypoxia in enhancing the
anti-tumour efficacy of AQ4N was shown using in vivo experi-
ments to combine AQ4N with a range of methods for inducing
tumour hypoxia e.g. combination with the pharmacological
vascular ‘steal’ agent hydralazine (Patterson et al, 2000) or
dimethylxanthenone acetic acid (Wilson et al, 1996) or by vascular
occlusion using clamping (Patterson et al, 2000); all showed
enhanced cytotoxicity of AQ4N.
AQ4N IN COMBINATION WITH RADIATION OR
CHEMOTHERAPEUTIC AGENTS IN VIVO
AQ4N has a relatively weak antitumour activity per se. When
combined with radiation in vivo a substantial enhancement of anti-
tumour efficacy is observed with a dose modification factor of
about two. This enhancement is found irrespective of whether
AQ4N is administered before or after the radiation exposure
providing strong evidence that this agent does act as a bioreductive
cytotoxin (Figure 2; McKeown et al, 1995, 1996; Patterson et al,
AQ4N: a new approach to hypoxia-activated cancer chemotherapy 1591
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Figure 2 Tumour growth delay when AQ4N was administered before or
after a single dose of radiation (12 Gy). AQ4N (200 mg kg–1) was
administered at a range of times up to 120 h before and 48 h after a single
dose of X-irradiation (12 Gy). Tumour growth delay (mean ± S.E.)
(6–18 animals per group) is plotted against time of administration. Bars show
the tumour growth delay obtained for AQ4N and radiation administered
alone. The results are the pooled data from three experiments (McKeown et
al, 1995)2000). Further evidence of the bioreductive nature of AQ4N was
shown using the MDAH-Mca-4 tumour in vivo; the anti-tumour
effect was enhanced with AQ4N when administered before or
after radiation (Wilson et al, 1996). Treatment of tumour-bearing
mice with AQ4N or radiation or a combination of both showed
distinct patterns of DNA damage. This was measured by the
‘Comet’ assay which was performed on cells isolated from excised
tumours subsequent to treatment (Hejmadi et al, 1996). Tumours
treated with AQ4N alone showed little evidence of DNA damage
whereas radiation alone showed immediate damage which was
repaired typically after 24 h. Combination of radiation with AQ4N
showed that the initial damage was repaired but a second
prolonged peak of DNA damage was observed. We speculate that
the prolonged damage is a result of formation of AQ4 and
concomitant inhibition of topoisomerase II in hypoxic cells forced
back into cycle as a consequence of ablation of the surrounding
oxic cell fraction.
McKeown et al (1995) also showed that not only was there an
enhancement of radiation cell kill but also the time at which the
drug was administered which was not critical. A maximal effect
was elicited when AQ4N was given up to 4 days before radiation.
Administration of AQ4N after radiation also gave a maximal
effect for at least 6 hours supporting the bioreductive nature of the
interaction (Figure 2). The interaction time fell off faster when
AQ4N was administered after radiation probably because reoxy-
genation will reduce the number of cells sensitive to all bioreduc-
tive drugs, including AQ4N. In a study of a faster-growing tumour
(SCCVII) maximal interaction was seen over a 16 hour period
irrespective of whether the drug was given before or after radiation
(Patterson et al, 2000). The shorter time of interaction may well
be explained by the faster growth rate of cells in the SCCVII
compared to the T50/80 tumour. Essentially the production of
AQ4 in hypoxic cells will compromise the cells in which it is
generated for some considerable time due to the stable and DNA
affinic nature of AQ4. The effect of AQ4 is likely to disappear in a
faster-growing tumour (i.e. SCCVII) more quickly than a slow-
growing tumour (e.g. T50/80) since new oxic cells will be
produced more quickly. Overall the relatively long interaction time
for both these tumour models (i.e. in the region of 1–4 days) high-
lights a potential benefit of AQ4N in the clinical setting since it
will facilitate scheduling with radiotherapy or oxic cell cytotoxins
(see below).
Following the success of the single dose radiation/AQ4N
combinations the efficacy of two different fractionated drug/
fractionated radiation combinations was investigated (McKeown
et al, 1995, 1996). Although maximal anti-tumour effects were
obtained when the drug was given daily there was an appreciable
effect when AQ4N dosing was on a once- or twice-weekly basis.
The results suggest that an appreciable effect has only a limited
dependence on drug dose or fractionation regimen. Enhancement
of the anti-tumour efficacy with multiple dosing may be explained
by the increased number of acutely hypoxic cells which will be
killed in a fractionated schedule (5 × 40 mg kg–1) as compared to a
single dose (200 mg kg–1). The results highlight that flexibility of
AQ4N scheduling should be possible.
Combination of AQ4N with thiotepa, cyclophosphamide and
cisplatin has also shown enhanced anti-tumour responses in
different tumour models in vivo (Patterson et al, 2000). With
cyclophosphamide the enhancement has a dose modification of
approximately 2 (Friery et al, 2000) and is of the same order as
that obtained in the single dose radiation experiments.
DOES AQ4N PROVIDE A THERAPEUTIC GAIN?
There is now good evidence that AQ4N has significant anti-
tumour efficacy in vivo when combined with a number of oxic cell
cytotoxins (see above). For this to translate into clinical benefit
AQ4N must provide a therapeutic gain. In support of this AQ4N
alone showed no bone marrow toxicity when given with a 6 h
interval in combination with cyclophosphamide or cisplatin
(Friery et al, 2000; Gallagher et al, personal communication).
AQ4N given 0.5 h prior to chemotherapy showed no, or only
limited, enhancement. The effect of scheduling AQ4N and
chemotherapy at intervals between 0.5–6 h has not been exam-
ined. Other normal tissue end-points have also been investigated.
Radiation did not enhance the toxicity of AQ4N to the eccrine
sweat glands of the mouse foot (McKeown et al, 1996). AQ4N
was not toxic to the mouse retina whereas certain nitro-based
bioreductive agents were significantly retino-toxic and even
Tirapazamine displayed measurable toxicity (Lee and Wilson,
2000). AQ4N in combination with radiation has only minimal
toxicity to mouse skin (McIntyre, personal communication).
SUMMARY
AQ4N enhances the anti-tumour efficacy of radiation and standard
chemotherapeutic agents with a dose-modifying factor of approxi-
mately 2.0. With careful scheduling no, or very little, additional
normal tissue toxicity should be observed. AQ4N is a bioreductive
prodrug of a potent, stable, reduction product which binds non-
covalently to DNA, facilitating antitumour activity in both
hypoxic and proximate oxic tumour cells. AQ4N is clearly
different from previously identified bioreductive drugs (see
Table 1). In particular AQ4N is the only bioreductive prodrug
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Table 1 Comparison of AQ4N with other clinically used bioreductive agents
Agent Chemical class Mechanism of Activating enzyme Active metabolite
action
AQ4N Alkylaminoanthraquinone-N-oxide DNA affinic Haemoproteins AQ4, stable
Topoisomerase II e.g. CYP’s, NOS DNA affinic agent
N-oxide inhibitor Oxygen insensitive
Tirapazamine Benzotriazene DNA double Flavoproteins Reactive nitroxyl
di-N-oxide strand breaks e.g. CPR, free radical,
nuclear reductases Redox cycles in air
Mitomycin C/ Mitosene DNA cross Flavoproteins Alkylating species
Porfiromycin (Indoloquinone) linking e.g. CPR, DTD Redox cycles in air
CYP = cytochrome P450; NOS = nitric oxide synthase; CPR = cytochrome P450 reductase; DTD = DT diaphorase.topoisomerase II inhibitor to enter clinical trials. Targeting this
enzyme, which is crucial to cell division, may help sensitize
tumours to repeated (fractionated) courses of radiotherapy. This is
because in principle, the bioreduction product of AQ4N can inhibit
the topoisomerase activity of hypoxic cells as they attempt to re-
enter the cell cycle.
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